Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.

被引：2
|
作者：
Westdorp, Harm
van Oort, Inge M.
Creemers, Jeroen H. A.
Schreibelt, Gerty
Mehra, Niven
de Goede, Anna L.
Hulsbergen-Van De Kaa, Christina
Figdor, Carl G.
Witjes, Alfred
Aarntzen, Erik H. J. G.
Mus, Roel D. M.
Gotthardt, Martin
Barentsz, Jelle O.
De Vries, Jolanda
Gerritsen, Winald R.
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[2] Radboud Inst Mol Life Sci, Nijmegen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
    Chowdry, Rajasree Pia
    Ledet, Elisa M.
    Phelan, Mary C.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [2] Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
    Creemers, J.
    Westdorp, H.
    van Oort, I.
    Schreibelt, G.
    Gorris, M.
    Mehra, N.
    Simons, M.
    de Goede, A.
    van Rossum, M.
    Croockewit, S.
    Figdor, C.
    Witjes, J. A.
    Aarntzen, E.
    Mus, R.
    Gotthardt, M.
    Barentsz, J.
    de Vries, J.
    Gerritsen, W. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Enzalutamide for Patients with castration-resistant Prostate Cancer
    Kessing, Richard
    AKTUELLE UROLOGIE, 2020, 51 (01)
  • [4] Cabazitaxel in patients with castration-resistant prostate cancer
    Falcao, Gil
    Carneiro, Cabrita
    Pinheiro, Luis Campos
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 25 - 25
  • [5] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [6] Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
    Westdorp, Harm
    Creemers, Jeroen H. A.
    van Oort, Inge M.
    Schreibelt, Gerty
    Gorris, Mark A. J.
    Mehra, Niven
    Simons, Michiel
    de Goede, Anna L.
    van Rossum, Michelle M.
    Croockewit, Alexandra J.
    Figdor, Carl G.
    Witjes, J. Alfred
    Aarntzen, Erik H. J. G.
    Mus, Roel D. M.
    Bruning, Mareke
    Petry, Katja
    Gotthardt, Martin
    Barentsz, Jelle O.
    de Vries, I. Jolanda M.
    Gerritsen, Winald R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [7] DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Briganti, Alberto
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Suzuki, Hiroyoshi
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Guan, Rongjin
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Apalutamide for the treatment of patients with castration-resistant prostate cancer
    Hauke, R.
    DRUGS OF TODAY, 2018, 54 (10) : 585 - 590
  • [9] Enzalutamide for Patients with castration-resistant Prostate Cancer Comment
    Kretschmer, Alexander
    AKTUELLE UROLOGIE, 2020, 51 (01)
  • [10] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
12345